Charles Mayes, MD
Interventional Cardiology · Dothan, ALNPI 1811916414
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,102 of the $4,400 with a category attached, or 70.5%. Medtronic accounts for 65.2% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2024 at $2,443 and has fallen 58.9% since, to $1,004 in 2025. That places this record below the midpoint for interventional cardiology clinicians in AL, where the typical reported total is $6,630.
Across 117 payments — averaging $37.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$262
- Abiomed$220
- Novartis$178
- E.r. Squibb & Sons, L.L.C.$158
- Abbott$134
- plus $582 from 13 others
Across 5 payments — averaging $8240.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Centerline Biomedical Inc.$41K
What the payments were for
- Travel & lodging$1,29829%
- Food & beverage$3,10271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 36 | $2,867 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $262 |
| Abiomed | 2 | $220 |
| Novartis | 12 | $178 |
| E.r. Squibb & Sons, L.L.C. | 10 | $158 |
| Abbott | 3 | $134 |
| Amgen | 8 | $122 |
| Irhythm Technologies, Inc. | 1 | $99 |
| Philips North America LLC | 3 | $49 |
| Merck | 3 | $43 |
| AstraZeneca | 3 | $39 |
| Johnson & Johnson | 3 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Penumbra, Inc. | 2 | $36 |
| Pfizer | 2 | $36 |
| Cardiovascular Systems Inc. | 2 | $28 |
| Boston Scientific | 2 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Elutia, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$1,787
- Impella$220
- Micra$111
- SYMPLICITY G3$101
How this compares
$4,400 in reported general payments places this provider in the 35th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 405 | $480,015 |
| EntrestoSacubitril/Valsartan | 101 | $157,388 |
| XareltoRivaroxaban | 119 | $148,455 |
| Repatha SureclickEvolocumab | 112 | $107,812 |
| MultaqDronedarone Hcl | 18 | $39,856 |
| JardianceEmpagliflozin | 23 | $17,517 |
| BrilintaTicagrelor | 21 | $13,183 |
| Ezetimibe | 257 | $6,002 |
| Ranolazine ErRanolazine | 38 | $5,381 |
| Valsartan | 197 | $5,317 |
| ClopidogrelClopidogrel Bisulfate | 326 | $4,418 |
| Metoprolol Succinate | 298 | $4,381 |
| Atorvastatin Calcium | 347 | $4,320 |
| Rosuvastatin Calcium | 246 | $3,654 |
| Dofetilide | 18 | $3,566 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $36 | $480,015405 claims |
| NovartisEntresto | $178 | $157,388101 claims |
| Johnson & JohnsonXarelto | $38 | $148,455119 claims |
| Sanofi-aventis U.S. LLCMultaq | $20 | $39,85618 claims |
| AstraZenecaBrilinta | $39 | $13,18321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Dothan
- Peter RaoDothan$13K
- Christopher IkeDothan$7K
- Gary RoubinBirmingham$157K
- Michael ButlerHuntsville$109K
- Pochana ReddyHuntsville$100K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
- John GallaMobile$82K
- Areen Al-TaieFlorence$69K
- Abdullah MahmoodBirmingham$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.